PSIWM
CRSP icon

Paradigm Strategies in Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Paradigm Strategies in Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10
Closed -$2K – 81
2021
Q2 		$2K Hold
10
– – ﹤0.01% 213
2021
Q1 		$1K Buy
+10
New +$1.51K ﹤0.01% 211

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Paradigm Strategies in Wealth Management's CRSP Position: Q3 2021 in Review

Paradigm Strategies in Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 10 shares — an estimated $2K sold.

Paradigm Strategies in Wealth Management first reported a position in CRSP in Q1 2021 and held it in 2 quarters. The position peaked at $2K in Q2 2021. 474 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Paradigm Strategies in Wealth Management reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Paradigm Strategies in Wealth Management sold 10 CRISPR Therapeutics shares in Q3 2021, an estimated $2K.
  • Paradigm Strategies in Wealth Management first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 2 quarters.
  • Paradigm Strategies in Wealth Management's CRISPR Therapeutics position peaked at $2K in Q2 2021.
  • 474 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Paradigm Strategies in Wealth Management's 13F filing for Q3 2021, filed 15 Oct 2021.